Terms: = Endocrine gland cancer AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616
132 results:
1. SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study.
Chen IY; Ettel MG; Bell PD; Huber AR; Findeis-Hosey JJ; Wang W; Hezel AF; Dunne RF; Drage MG; Agostini-Vulaj D
Hum Pathol; 2024 Feb; 144():40-45. PubMed ID: 38307342
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
3. Divergent Lineage Markers in Anaplastic Thyroid Carcinoma.
Mneimneh WS; Asa SL
Am J Surg Pathol; 2024 Feb; 48(2):230-237. PubMed ID: 37972932
[TBL] [Abstract] [Full Text] [Related]
4. Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia.
Xu J; Weisman PS
Int J Gynecol Pathol; 2024 May; 43(3):302-307. PubMed ID: 37922945
[TBL] [Abstract] [Full Text] [Related]
5. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract] [Full Text] [Related]
6. Pathogenic germline variants in smarca4 and further cancer predisposition genes in early onset ovarian cancer.
Herold N; Schmolling J; Ernst C; Ataseven B; Blümcke B; Schömig-Markiefka B; Heikaus S; Göhring UJ; Engel C; Lampe B; Rhiem K; Harter P; Hauke J; Schmutzler RK; Hahnen E
Cancer Med; 2023 Jul; 12(14):15256-15260. PubMed ID: 37345881
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract] [Full Text] [Related]
8. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
Blatnik A; Dragoš VŠ; Blatnik O; Stegel V; Klančar G; Novaković S; Drev P; Žagar T; Merlo S; Škof E; Bojadžiski MP; Strojnik K; Krajc M
Arch Pathol Lab Med; 2024 Mar; 148(3):299-309. PubMed ID: 37270804
[TBL] [Abstract] [Full Text] [Related]
9. brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway.
Araki O; Tsuda M; Omatsu M; Namikawa M; Sono M; Fukunaga Y; Masuda T; Yoshikawa T; Nagao M; Ogawa S; Masuo K; Goto N; Muta Y; Hiramatsu Y; Maruno T; Nakanishi Y; Koyasu S; Masui T; Hatano E; Saur D; Fukuda A; Seno H
Oncogene; 2023 Jun; 42(26):2139-2152. PubMed ID: 37198398
[TBL] [Abstract] [Full Text] [Related]
10. Borderline With Bad Behavior: An Unusual Low-grade Serous Carcinoma With Dedifferentiation From a Serous Borderline Tumor.
Strickland AL; Maniar KP; Tanner E; Shanes E; Jennings L; Wei JJ
Int J Gynecol Pathol; 2023 May; 42(3):241-246. PubMed ID: 36867463
[TBL] [Abstract] [Full Text] [Related]
11. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
12. Ovarian high-grade serous carcinoma cells with low smarca4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract] [Full Text] [Related]
13. The Emerging Role of Chromatin Remodeling Complexes in Ovarian cancer.
Vaicekauskaitė I; Sabaliauskaitė R; Lazutka JR; Jarmalaitė S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430148
[TBL] [Abstract] [Full Text] [Related]
14. Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report.
Coşkun Ç; Kurucu N; Usubutun A; Soyer T; Ozcan HN; Çelik Ertaş NB; Kutluk T
J Pediatr Adolesc Gynecol; 2023 Apr; 36(2):112-115. PubMed ID: 36243275
[TBL] [Abstract] [Full Text] [Related]
15. Network Pharmacology, Molecular Docking, and Experimental Validation to Unveil the Molecular Targets and Mechanisms of Compound Fuling Granule to Treat Ovarian cancer.
Li Z; Liu Q; Zhu Y; Wu L; Liu W; Li J; Zhang Z; Tao F
Oxid Med Cell Longev; 2022; 2022():2896049. PubMed ID: 36062197
[TBL] [Abstract] [Full Text] [Related]
16. Case report of bilateral ovarian fibromas associated with de novo germline variants in PTCH1 and smarca4.
Higashimoto T; Smith CH; Hopkins MR; Gross J; Xing D; Lee JW; Morris T; Bodurtha J
Mol Genet Genomic Med; 2022 Sep; 10(9):e2005. PubMed ID: 35775118
[TBL] [Abstract] [Full Text] [Related]
17. The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.
Andonegui-Elguera S; Silva-Román G; Peña-Martínez E; Taniguchi-Ponciano K; Vela-Patiño S; Remba-Shapiro I; Gómez-Apo E; Espinosa-de-Los-Monteros AL; Portocarrero-Ortiz LA; Guinto G; Moreno-Jimenez S; Chavez-Macias L; Saucedo R; Basurto-Acevedo L; Lopez-Felix B; Gonzalez-Torres C; Gaytan-Cervantes J; Ayala-Sumuano JT; Burak-Leipuner A; Marrero-Rodríguez D; Mercado M
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563252
[TBL] [Abstract] [Full Text] [Related]
18.
Nakra T; Kakkar A; Mathur SR; Jain D; Kumar S
Int J Surg Pathol; 2023 Feb; 31(1):104-109. PubMed ID: 35466749
[No Abstract] [Full Text] [Related]
19. The value of SOX2 in the differential diagnosis of smarca4 (brg1)-deficient uterine neoplasms.
Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
[Next]
